Skip to main content

Day: February 22, 2024

Xos, Inc., Winnebago Announce Partnership and Development of Fully Electric Specialty Vehicle Chassis

LOS ANGELES and FOREST CITY, Iowa, Feb. 22, 2024 (GLOBE NEWSWIRE) — Xos, Inc. (NASDAQ: XOS), a leading manufacturer of electric commercial vehicles, and Winnebago®, the flagship brand of outdoor lifestyle product manufacturer Winnebago Industries (NYSE: WGO), are pleased to announce an exciting partnership and development of a fully electric chassis for Winnebago’s Specialty Vehicles division. This chassis utilizes proven Xos battery and electronics technology and is customized for Winnebago’s unique commercial applications. “We constantly seek new ways to enhance our customers’ mission, and our partnership with Xos is an important next step in our efforts,” said Robert Kim, director for Winnebago’s Specialty Vehicles division. “The near-term demand for zero-emission vehicle options from our Specialty Vehicle division continues...

Continue reading

PharmAla named an Intellectual Property Ontario Client

IPON to grant PharmAla an initial grant of $35,000, with a further total grant of $100,000 available in subsequent funding calls VANCOUVER, British Columbia, Feb. 22, 2024 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules) announces today that it has been accepted as a client of Intellectual Property Ontario (IPON). IPON works with innovators, businesses, and researchers to provide access to expert IP education, financial support, and mentorship to help maximize the value of IP, strengthen their capacity to grow, compete in the market, and enhance research and commercialization outcomes. PharmAla is further pleased to note...

Continue reading

Gracell Biotechnologies Acquisition Completed

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) — Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of...

Continue reading

GoHealth to Announce Fourth Quarter and Year End 2023 Results on March 14, 2024

CHICAGO, Feb. 22, 2024 (GLOBE NEWSWIRE) — GoHealth, Inc. (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its fourth quarter and full year 2023 financial results on the morning of March 14, 2024. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Jason Schulz, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available via GoHealth’s Investor Relations website, https://investors.gohealth.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call. About GoHealth, Inc. GoHealth is a leading health insurance marketplace and Medicare-focused...

Continue reading

Talkspace Announces Fourth Quarter and Full Year 2023 Results

4Q 2023 Payor revenue grew 138% year-over-year 4Q 2023 Operating expenses of $23.6 million, down 37% year-over-year 4Q 2023 Net loss of $1.3 million; Adjusted EBITDA1 loss of $0.3 million, an improvement of 97% year-over-year Provides 2024 guidance with revenue $185-$195 million and adjusted EBITDA1 $4-$8 million Announces Initial Share Repurchase Program of $15M NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) — Talkspace, Inc. (NASDAQ: TALK), today reported fourth quarter and full year 2023 financial results.    Three Months   Full YearUnaudited    Year Ended December 31, 2023   Results   Variance from Prior Year %   Results   Variance from Prior Year %(In thousands unless otherwise noted)                Number of eligible lives at year end (in millions)     131       42%       131       42%  Number of completed Payor...

Continue reading

Hudson Technologies To Host Conference Call To Discuss Fourth Quarter 2023 Results

WOODCLIFF LAKE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) — Hudson Technologies, Inc. (NASDAQ: HDSN) will host a conference call and webcast on Wednesday, March 6, 2024 at 5:00 p.m. Eastern Time to discuss the Company’s fourth quarter 2023 results. To access the live webcast, log onto the Hudson Technologies website at www.hudsontech.com, and click on “Events”. To participate in the call by phone, dial (877) 545-0523 approximately five minutes prior to the scheduled start time. International callers please dial (973) 528-0016. Callers should use entry code: 432603 A replay of the teleconference will be available until April 5, 2024 and may be accessed by dialing (877) 481-4010. International callers may dial (919) 882-2331. Callers should use conference ID: 49792. About Hudson Technologies Hudson Technologies, Inc. is a leading provider...

Continue reading

Kineta to Present New Preclinical Data on its Anti-VISTA Antibody KVA12123 in Acute Myeloid Leukemia at the AACR Blood Cancer Discovery Symposium

SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) — Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it will present new preclinical data on KVA12123, the Company’s anti-VISTA antibody, in acute myeloid leukemia (AML) at the American Association for Cancer Research (AACR) Blood Cancer Discovery Symposium, to be held on March 4-6 in Boston, Massachusetts. Thierry Guillaudeux, Ph.D., Chief Scientific Officer of Kineta, will be presenting the poster. Presentation DetailsPoster Title: VISTA a potential new Immuno-oncology therapeutic target to treat human Acute Myeloid LeukemiaDate and Time:   Tuesday, March 5, 2024Time:   6:45 P.M.– 8:45 P.M. Eastern TimeLocation: Westin Copley Place P21 The abstract will...

Continue reading

Amerant Investments Partners with iCapital to Expand US and LATAM Access to Alternative Investment Opportunities

The partnership offers Amerant advisors and HNW clients access to a broad private market menu along with iCapital’s technology and comprehensive solutions MIAMI, ZURICH & NEW YORK, Feb. 22, 2024 (GLOBE NEWSWIRE) — Amerant Investments, a wholly owned subsidiary of Amerant Bank – the largest community bank in Florida – announced today that it has entered into a strategic relationship with iCapital[1], the global fintech platform driving the world’s alternative investment marketplace for the wealth management industry. This collaboration will provide Amerant Investment’s financial advisors, along with their clients, access to private market opportunities and analytics. The partnership will also entail oversight of the entire investment and education experience through a unified technology platform and operating system....

Continue reading

Workhorse Group Adds Riverview International Trucks as its Fifth California Dealer

CINCINNATI, Feb. 22, 2024 (GLOBE NEWSWIRE) — Workhorse Group Inc. (Nasdaq: WKHS) (“Workhorse” or “the Company”), an American technology company focused on pioneering the transition to zero-emission commercial vehicles, today announced it has added Riverview International Trucks (“Riverview”) as its latest vehicle dealer, bringing the Company’s total dealer count in California to five. With locations in West Sacramento and Redding, Riverview is a family owned and operated full-service heavy-duty truck dealership that has been serving Northern California since 1981. Riverview’s customer-first approach has allowed it to forge longstanding partnerships with leading businesses in California. Customers have relied on Riverview for over four decades to provide quality vehicles from leading OEMs as well as full-service lease, contract...

Continue reading

Capricor Therapeutics to Present Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update on February 29

Company to Host Conference Call, February 29, 2024 at 4:30 p.m. ET SAN DIEGO, Feb. 22, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, will release its financial results for the fourth quarter and full year ended December 31, 2023, after the market close on Thursday, February 29, 2024. Management will then host a webcast and conference call at 4:30 p.m. ET on February 29.Title: Capricor Therapeutics Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Update Conference Call and Webcast   Date: Thursday, February 29, 2024   Time: 4:30 p.m. ET   Conference Call Details: Toll-Free: 1-888-886-7786International: 1-416-764-8658Conference ID: 83986877 Participants...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.